相关实验视频
Updated: May 28, 2025

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
36.6K
在阿尔茨海默病中,神经质斑块的铁和病变发生在阿尔茨海默病中
Wolfgang J Streit1, Leah Phan1, Ingo Bechmann2
1Department of Neuroscience, University of Florida College of Medicine, Gainesville, Florida.
Pharmacological reviews
|February 14, 2025
概括
大脑铁的升高,而不是粉样质斑块,驱动着阿尔茨海默氏症 (AD) 病原体. 铁过载导致神经元死亡和铁亡,导致神经质斑块和痴呆症,挑战了粉样蛋白级联理论.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 生物化学 生物化学
背景情况:
- 神经性斑块是阿尔茨海默病 (AD) 的标志,传统上与粉样β (Aβ) 蛋白有关.
- 粉样蛋白级联假说假设Aβ毒性驱动神经质斑块和神经纤维状结形成.
- 最近的人类尸检研究表明,一种涉及铁过载的替代机制.
研究的目的:
- 审查自由氧化还原活性铁在阿尔茨海默氏症病变发生过程中的作用.
- 提出支持铁介导神经元退化和铁死作为主要事件的证据.
- 通过从临床前AD阶段的发现来挑战粉样蛋白级联理论.
主要方法:
- 对人类死后研究的审查,重点关注早期的临床前阿尔茨海默病.
- 分析人类叶的证据.
- 综合发现,构建一个修订的AD病变发生的模型.
主要成果:
- 铁过载和铁灭会引发神经元退化,先于Aβ沉积.
- 神经质斑块和神经纤维状结是由铁载体,退化的神经元形成的.
- 大脑铁的积累是AD病理发展的所有阶段的核心.
结论:
- 大脑铁含量升高,而不是Aβ,是阿尔茨海默氏病发病的关键驱动因素.
- 铁介导的细胞死亡和铁制机制是神经质斑块形成的关键.
- 以铁为中心的阿尔茨海默氏症病原体的修订理解可能指导新的治疗策略.
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429
Necrosis
4.0K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.0K
Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429
Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K

